| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Pneucolin |
| Other names | DelNS1-nCoV-RBD LAIV[1] |
| Routes of administration | Intranasal |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
|
Medical response |
|
DelNS1-2019-nCoV-RBD-OPT is aCOVID-19 vaccine developed by Beijing Wantai Biological,Xiamen University and theUniversity of Hong Kong.[3][4][5] It is administered as a single dose intranasal spray.[6]
On 14 December 2022, the vaccine was listed by theNational Health Commission of China as a secondarybooster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[7]
This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |